Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus BETATREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus BETATREX.
ARAZLO vs BETATREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Betamethasone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and alter connective tissue response.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Adults: 1 gram intravenously every 24 hours. For severe infections, 1 gram every 12 hours may be used.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life is 8-12 hours in adults with normal renal function, allowing twice-daily dosing.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Renal elimination of unchanged drug accounts for approximately 60-70% of the dose; biliary excretion contributes about 20-25%, with the remainder eliminated via feces.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid